{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:31:26Z","timestamp":1775799086838,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Centers for the Disease Control and Prevention"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.vaccine.2018.08.010","type":"journal-article","created":{"date-parts":[[2018,8,11]],"date-time":"2018-08-11T12:15:23Z","timestamp":1533989723000},"page":"5732-5737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults"],"prefix":"10.1016","volume":"36","author":[{"given":"Huong Q.","family":"McLean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy Parker","family":"Fiebelkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adaeze","family":"Ogee-Nwankwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LiJuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebola","family":"Adebayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Icenogle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.08.010_b0005","series-title":"Vaccines","first-page":"688","article-title":"Rubella vaccine","author":"Reef","year":"2013"},{"issue":"16","key":"10.1016\/j.vaccine.2018.08.010_b0010","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1001\/jama.284.16.2053","article-title":"Measles-mumps-rubella vaccine in the Italian armed forces","volume":"284","author":"D'Amelio","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.010_b0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archpedi.1969.02100040303027","article-title":"Grayston JT. Prevention of rubella during an epidemic on Taiwan. HPV-77 and RA 27\u20133 rubella vaccines administered subcutaneously and intranasally HPV-77 vaccine mixed with mumps and-or measles vaccines","volume":"118","author":"Beasley","year":"1969","journal-title":"Am J Dis Child"},{"issue":"6","key":"10.1016\/j.vaccine.2018.08.010_b0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/jama.1970.03170320015002","article-title":"Rubella vaccination during an epidemic","volume":"213","author":"Furukawa","year":"1970","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.08.010_b0025","unstructured":"McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-04): 1-34."},{"issue":"Suppl 9","key":"10.1016\/j.vaccine.2018.08.010_b0030","first-page":"1","article-title":"Measles prevention","volume":"38","author":"Centers for Disease Control and Prevention","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2018.08.010_b0035","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/505943","article-title":"The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement","volume":"43","author":"Reef","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.010_b0040","first-page":"148","article-title":"Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience","volume":"168","author":"Papania","year":"2014","journal-title":"JAMAPediatr"},{"issue":"6","key":"10.1016\/j.vaccine.2018.08.010_b0045","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1086\/605410","article-title":"Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine","volume":"200","author":"LeBaron","year":"2009","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2018.08.010_b0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00006454-199608000-00010","article-title":"Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years","volume":"15","author":"Johnson","year":"1996","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"10.1016\/j.vaccine.2018.08.010_b0055","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.vaccine.2005.12.015","article-title":"Waning antibodies in measles and rubella vaccinees\u2013a longitudinal study","volume":"24","author":"Kremer","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.08.010_b0060","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1542\/peds.2012-0177","article-title":"Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak","volume":"130","author":"Ogbuanu","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.08.010_b0065","article-title":"Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control- Guam 2009\u20132010","author":"Nelson","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"29","key":"10.1016\/j.vaccine.2018.08.010_b0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.15585\/mmwr.mm6529a2","article-title":"Mumps outbreak at a university and recommendation for a third dose of measles-mumps-rubella vaccine \u2013 Illinois, 2015\u20132016","volume":"65","author":"Albertson","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.010_b0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15585\/mmwr.mm6701a7","article-title":"Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak","volume":"67","author":"Marin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-7","key":"10.1016\/j.vaccine.2018.08.010_b0080","first-page":"1","article-title":"Advisory committee on immunization practices, centers for disease control prevention. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Manning","year":"2011","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.010_b0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.vaccine.2007.11.035","article-title":"Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000\u20132004","volume":"26","author":"Eick","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.010_b0090","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archpedi.161.3.294","article-title":"Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment","volume":"161","author":"LeBaron","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.010_b0095","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1542\/peds.2006-0678","article-title":"Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine","volume":"118","author":"LeBaron","year":"2006","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.010_b0100","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1086\/596207","article-title":"Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine","volume":"199","author":"LeBaron","year":"2009","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.010_b0105","doi-asserted-by":"crossref","first-page":"ofu094","DOI":"10.1093\/ofid\/ofu094","article-title":"Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine","volume":"1","author":"Fiebelkorn","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.08.010_b0110","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/infdis\/jiv555","article-title":"Measles virus neutralizing antibody response, cell-mediated immunity, and immunoglobulin g antibody avidity before and after receipt of a third dose of measles, mumps, and rubella vaccine in young adults","volume":"213","author":"Fiebelkorn","year":"2016","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.010_b0115","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1128\/CVI.00681-13","article-title":"High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers","volume":"21","author":"Lambert","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.08.010_b0120","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1086\/378691","article-title":"Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age","volume":"189","author":"Redd","year":"2004","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.010_b0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1542\/peds.68.1.18","article-title":"Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27\/3) virus vaccines, singly and in combination","volume":"68","author":"Lerman","year":"1981","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.010_b0130","first-page":"258","article-title":"Vaccination of schoolgirls against rubella. Assessment of serological status and a comparative trial of Wistar RA 27\/3 and Cendehill strain live attenuated rubella vaccines in 13-year-old schoolgirls in Dudley","volume":"29","author":"Freestone","year":"1975","journal-title":"Br J Prev Soc Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.010_b0135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3181\/00379727-165-40979","article-title":"Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27\/3 rubella virus","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2018.08.010_b0140","first-page":"155","article-title":"Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age","volume":"100","author":"Singh","year":"1994","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.010_b0145","first-page":"511","article-title":"A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12\u201324 months of age","volume":"30","author":"Gatchalian","year":"1999","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2018.08.010_b0150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00006454-199901000-00011","article-title":"Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children","volume":"18","author":"Usonis","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"37\u201338","key":"10.1016\/j.vaccine.2018.08.010_b0155","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1016\/j.vaccine.2007.07.008","article-title":"Long-term persistence of antibodies after one or two doses of MMR-vaccine","volume":"25","author":"Vandermeulen","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.010_b0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00000441-198003000-00002","article-title":"Live attenuated rubella virus vaccine: comparison of responses to HPV-77-DE5 and RA 27\/3 strains","volume":"279","author":"Gershon","year":"1980","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.010_b0165","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/inf.1975.7.issue-3.03","article-title":"Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines","volume":"7","author":"Grillner","year":"1975","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.08.010_b0170","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S0022172400021720","article-title":"Vaccination of adults with Wistar RA 27\/3 rubella vaccine","volume":"69","author":"Freestone","year":"1971","journal-title":"J Hyg (Lond)"},{"issue":"5","key":"10.1016\/j.vaccine.2018.08.010_b0175","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oxfordjournals.aje.a121272","article-title":"Comparative trials of RA 27\u20133 and Cendehill rubella vaccines in adult and adolescent females","volume":"93","author":"Fogel","year":"1971","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.010_b0180","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/infdis\/148.4.639","article-title":"Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus","volume":"148","author":"O'Shea","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.010_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2018.1475814","article-title":"Response to third rubella vaccine dose","author":"Siira","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2018.08.010_b0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ajcp\/106.2.170","article-title":"Rubella immunity. Defining the level of protective antibody","volume":"106","author":"Skendzel","year":"1996","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.vaccine.2018.08.010_b0195","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JCM.00383-16","article-title":"Assessing Immunity to Rubella Virus: a Plea for Standardization of IgG (Immuno)assays","volume":"54","author":"Bouthry","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.08.010_b0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00251-010-0423-6","article-title":"SNP\/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine","volume":"62","author":"Dhiman","year":"2010","journal-title":"Immunogenetics"},{"issue":"7","key":"10.1016\/j.vaccine.2018.08.010_b0205","doi-asserted-by":"crossref","first-page":"e11806","DOI":"10.1371\/journal.pone.0011806","article-title":"Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity","volume":"5","author":"Ovsyannikova","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.08.010_b0210","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2172-11-48","article-title":"Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment","volume":"11","author":"Pankratz","year":"2010","journal-title":"BMC Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18311174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18311174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T02:32:52Z","timestamp":1661740372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18311174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":42,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0264410X18311174"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}